PMID- 32748747
OWN - NLM
STAT- MEDLINE
DCOM- 20211122
LR  - 20211122
IS  - 1873-5576 (Electronic)
IS  - 1568-0096 (Linking)
VI  - 20
IP  - 10
DP  - 2020
TI  - Advances in Regulating Tumorigenicity and Metastasis of Cancer Through TrkB 
      Signaling.
PG  - 779-788
LID - 10.2174/1568009620999200730183631 [doi]
AB  - The clinical pathology of various human malignancies is supported by tropomyosin 
      receptor kinase (Trk) B TrkB which is a specific binding receptor of the 
      brain-derived neurotrophic factor (BDNF). TrkB and TrkB fusion proteins have been 
      observed to be over-expressed in many cancer patients. Moreover, these proteins 
      have been observed in multiple types of cells. A few signaling pathways can be 
      modulated by the abnormal activation of the BDNF/TrkB pathway. These signaling 
      pathways include PI3K/Akt pathway, transactivation of EGFR, phospholipase C-gamma 
      (PLCgamma) pathway, Ras-Raf-MEK-ERK pathway, Jak/STAT pathway, and nuclear factor 
      kappalight- chain-enhancer of activated B cells (NF-kB) pathway. The BDNF/TrkB 
      pathway, when overexpressed in tumors, is correlated with reduced clinical 
      prognosis and short survival time of patients. Targeting the BDNF/TrkB pathway 
      and the use of Trk inhibitors, such as entrectinib, larotrectinib, etc. are 
      promising methods for targeted therapy of tumors. The present review provides an 
      overview of the role of the TrkB pathway in the pathogenesis of cancer and its 
      value as a potential therapeutic target.
CI  - Copyright(c) Bentham Science Publishers; For any queries, please email at 
      epub@benthamscience.net.
FAU - Zou, Wujun
AU  - Zou W
AD  - Department of Otorhinolaryngology, Head and Neck Surgery, Affiliated Hospital of 
      Southwest Medical University, Luzhou, Sichuan Province, China.
FAU - Hu, Xiaoyan
AU  - Hu X
AD  - Department of Pathogenic Biology, School of Basic Medicine, Southwest Medical 
      University, Luzhou, Sichuan, China.
FAU - Jiang, Liang
AU  - Jiang L
AD  - Department of Otorhinolaryngology, Head and Neck Surgery, Affiliated Hospital of 
      Southwest Medical University, Luzhou, Sichuan Province, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - Netherlands
TA  - Curr Cancer Drug Targets
JT  - Current cancer drug targets
JID - 101094211
RN  - 0 (Membrane Glycoproteins)
RN  - 0 (Protein Kinase Inhibitors)
RN  - EC 2.7.10.1 (Receptor, trkB)
RN  - EC 2.7.10.1 (tropomyosin-related kinase-B, human)
SB  - IM
MH  - Humans
MH  - MAP Kinase Signaling System
MH  - Membrane Glycoproteins/antagonists & inhibitors/*metabolism
MH  - *Molecular Targeted Therapy
MH  - Neoplasm Metastasis
MH  - Neoplasms/drug therapy/metabolism/*pathology
MH  - Protein Kinase Inhibitors/therapeutic use
MH  - Receptor, trkB/antagonists & inhibitors/*metabolism
MH  - Signal Transduction
OTO - NOTNLM
OT  - TrkB
OT  - somatic mutation
OT  - targeted therapies
OT  - trkB fusion
OT  - trkB inhibitor
OT  - tumorigenicity
EDAT- 2020/08/05 06:00
MHDA- 2021/11/23 06:00
CRDT- 2020/08/05 06:00
PHST- 2020/03/02 00:00 [received]
PHST- 2020/06/27 00:00 [revised]
PHST- 2020/06/29 00:00 [accepted]
PHST- 2020/08/05 06:00 [pubmed]
PHST- 2021/11/23 06:00 [medline]
PHST- 2020/08/05 06:00 [entrez]
AID - CCDT-EPUB-108739 [pii]
AID - 10.2174/1568009620999200730183631 [doi]
PST - ppublish
SO  - Curr Cancer Drug Targets. 2020;20(10):779-788. doi: 
      10.2174/1568009620999200730183631.